Merck to Acquire Bio-Techne in $11 Billion Life Sciences Deal
Merck KGaA has announced an $11.3 billion agreement to acquire U.S.-based Bio-Techne, marking the German pharmaceutical giant’s largest acquisition since 2014. The deal, which offers $73 per share—a 24% premium over the closing price on Wednesday—is designed to bolster Merck’s life sciences division by integrating Bio-Techne’s extensive portfolio of research reagents, proteins, and analytical instruments … Read more